Russell Angus C.
SEC insider (Form 3/4/5 filer). CIK 0001534002. Director at Lineage Cell Therapeutics, Inc. (LCTX) and 2 other issuers. 6 reported Form 4/5 transactions since Sep 2024; latest on Jul 1, 2026. Located in CARLSBAD, CA.
Companies Russell Angus C. has filed insider reports for
- Lineage Cell Therapeutics, Inc. (LCTX): Director
- Structure Therapeutics Inc. (GPCR): Director
- Revance Therapeutics, Inc. (RVNC): Director
Russell Angus C.
CIK: 0001534002
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jul 1, 2026LCTX
Lineage Cell Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
125K shares- - Jun 17, 2026GPCR
Structure Therapeutics Inc.
AwardDirectShare Option (right to buy)
39.5K shares- - Jul 1, 2025LCTX
Lineage Cell Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
75K shares- - Jun 23, 2025GPCR
Structure Therapeutics Inc.
AwardDirectShare Option (right to buy)
42.8K shares- - Feb 6, 2025RVNC
Revance Therapeutics, Inc.
DispositionDirect15K shares- - Feb 4, 2025RVNC
Revance Therapeutics, Inc.
Tender OfferDirect36.5K shares at avg. $3.65$133K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 1, 2026 |  LCTX Lineage Cell Therapeutics, Inc. | Award Stock Option (Right to Buy) | 125,000 | - | - | Direct |
| Jun 17, 2026 |  GPCR Structure Therapeutics Inc. | Award Share Option (right to buy) | 39,453 | - | - | Direct |
| Jul 1, 2025 | LCTX Lineage Cell Therapeutics, Inc. | Award Stock Option (Right to Buy) | 75,000 | - | - | Direct |
| Jun 23, 2025 | GPCR Structure Therapeutics Inc. | Award Share Option (right to buy) | 42,833 | - | - | Direct |
| Feb 6, 2025 |  RVNC Revance Therapeutics, Inc. | Disposition | 15,000 | - | - | Direct |
| Feb 4, 2025 | RVNC Revance Therapeutics, Inc. | Tender Offer | 36,506 | $3.65 | $133,247 | Direct |
1-6 of 6 transactions